2023 World Conference on Lung Cancer (Posters)-P2.14. Patient-Reported Outcomes from IMfirst: Chemotherapy Plus Atezolizumab in a Real-World Setting of Extensive-Stage SCLC

P2.14. Patient-Reported Outcomes from IMfirst: Chemotherapy Plus Atezolizumab in a Real-World Setting of Extensive-Stage SCLC - PDF(Slides)

Back to course

Pdf Summary

This document presents the patient-reported outcomes (PROs) from the IMfirst study, which evaluated the use of chemotherapy plus atezolizumab (ATZ) in patients with extensive-stage small cell lung cancer (ES-SCLC). The PROs were assessed using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life-Core 30 (QLQ-C30) and Lung Cancer module (QLQ-LC13) questionnaires, as well as the EuroQol 5 domain (EQ-5D-5L) questionnaire. <br /><br />The results showed that most social functions and health-related quality of life (HRQoL) improved compared to baseline and remained above baseline throughout the study visits. Lung cancer-related symptoms, such as appetite loss, chest pain, and cough, showed a consistent improvement. Treatment-related symptoms, such as alopecia and insomnia, also showed clinically meaningful changes.<br /><br />The EQ-5D-5L questionnaire revealed that most patients had no self-care problems, mobility issues, or anxiety/depression during the study. The percentage of patients reporting moderate to extreme problems with usual activities or pain/discomfort decreased in the maintenance phase compared to the induction phase. The mean visual analogue scale (VAS) score for HRQoL improved during the induction phase and remained above baseline throughout the study visits.<br /><br />The document also provides information on the questionnaires used, their scoring system, and the relevance of a 10-point score change from baseline. Additionally, it highlights the positive impact of monitoring PROs during cancer treatment on symptom control, patient satisfaction, communication, HRQoL, and survival.<br /><br />The IMfirst study enrolled 155 patients and allowed for the inclusion of patients with certain characteristics that were excluded in previous studies. The PRO data from this study are consistent with the results observed in previous studies, suggesting a positive benefit-risk profile of ATZ in a real-world clinical setting.<br /><br />Overall, the findings from the IMfirst study support the use of chemotherapy plus ATZ as a first-line treatment option for patients with ES-SCLC, as it improves survival without negatively impacting lung cancer-related symptoms, physical function, or HRQoL.

Asset Subtitle

Manuel Dómine Gómez

Meta Tag

Speaker Manuel Dómine Gómez

Topic SCLC & Neuroendocrine Tumors: First Line Therapy

Keywords

patient-reported outcomes

IMfirst study

chemotherapy

atezolizumab

extensive-stage small cell lung cancer

HRQoL

lung cancer-related symptoms

treatment-related symptoms

EQ-5D-5L

survival improvement